Compare AMC ENTERTAINMENT HOLDINGS, INC. (AMC) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AMC ENTERTAINMENT HOLDINGS, INC. vs Twist Bioscience Corp — how do they compare? AMC ENTERTAINMENT HOLDINGS, INC. trades at $1.88 (market cap $1.69B), while Twist Bioscience Corp trades at $90.35 (market cap $5.64B). The key difference: Twist Bioscience Corp is far larger — about 3.3× AMC ENTERTAINMENT HOLDINGS, INC.'s market cap, and AMC ENTERTAINMENT HOLDINGS, INC. pays a 0.11% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| AMC | TWST | |
|---|---|---|
Market Cap | $1.69B | $5.64B |
Sector | Media | Health |
52-Week High | $3.54 | $102.88 |
52-Week Low | $0.95 | $24.16 |
Enterprise Value | $9.28B | $5.57B |
Dividend Yield | 0.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMC trades at $1.89, down 0.53% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 EPS of -$0.36, missing expectations, while revenue trends show modest growth from $4.6B in 2024 to $4.85B in 2025. Recent news highlights box office recovery optimism and a $200 million stock offering that caused dilution concerns.
Outlook remains challenging with persistent net losses and high debt burden, though analyst consensus targets $1.90 with 32% buy ratings. Key risks include ongoing dilution from equity offerings, competitive pressures in entertainment, and the need for sustained box office recovery to improve cash flow and profitability.
Twist Bioscience (TWST) trades at $90.64, down 3.24% today, with a bullish technical signal from moving averages and ADX indicators. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a net income margin of -19.85%. Recent developments include AI-driven drug discovery collaborations and expansion of clonal genes offerings, positioning TWST in the growing synthetic biology market.
While analyst consensus is strongly bullish (77% buy ratings) with a $87.88 price target, investors face significant risks from persistent cash burn and competitive pressures. The stock's valuation appears stretched at 13.46x sales despite negative earnings, requiring careful monitoring of path to profitability and execution on AI partnerships for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMC ENTERTAINMENT HOLDINGS, INC.
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
